Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 12/20 | 0.81 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.44 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3870564 | 0.90 | PGR (1.00) | PGRNR3C1NR3C2AR | |
| SCHEMBL10917430 | 0.84 | PGR (0.60) | PGRNR3C1NR3C2AR | |
| SCHEMBL4176817 | 0.77 | PGR (0.72) | PGRCHEK1NR3C1NR3C2AR | |
| SCHEMBL3378790 | 0.76 | PGR (0.72) | PGRNR3C1NR3C2AR | |
| SCHEMBL4171898 | 0.75 | PGR (0.70) | PGRCHEK1BRD4HDAC4HDAC8 | |
| SCHEMBL3871920 | 0.74 | PGR (1.00) | PGR | |
| SCHEMBL3872475 | 0.73 | PGR (0.74) | PGRNR3C1NR3C2AR | |
| SCHEMBL4406856 | 0.71 | CRBN (0.57) | PGRCHEK1BRD4HDAC4HDAC8 | |
| SCHEMBL5225707 | 0.71 | PGR (1.00) | PGRCHEK1BRD4HDAC4HDAC8 | |
| SCHEMBL3880052 | 0.71 | PGR (0.76) | PGRNR3C1NR3C2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111802-A1 | CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | WYETH (US) | 2009-04-30 | — | — | US | disclosed |
| US-7488822-B2 | Cyclocarbamate derivatives as progesterone receptor modulators | WYETH (US) | 2009-02-10 | — | — | US | disclosed |
| US-20040186101-A1 | Cyclocarbamate derivatives as progesterone receptor modulators | WYETH | 2004-09-23 | — | — | US | disclosed |
| EP-1173210-B1 | CONTRACEPTIVE COMPOSITIONS CONTAINING ANTIPROGESTINIC AND PROGESTINIC | WYETH CORP (US) | 2004-09-15 | — | — | EP | disclosed |
| US-6759408-B2 | CYCLIC COMBINATION THERAPIES AND REGIMENS UTILIZING SUBSTITUTED INDOLINE DERIVATIVE COMPOUNDS WHICH ARE ANTAGONISTS OF THE PROGESTERONE RECEPTOR | WYETH | 2004-07-06 | — | — | US | disclosed |
| US-6713478-B2 | SUCH AS 8-BROMO-6-(3-CHLORO-4-FLUOROPHENYL)-4,4-DIMETHYL-1,4-DIHYDRO-2H-3,1 -BENZOXAZIN-2-ONE; PROGESTERONE RECEPTOR ANTAGONISTS | WYETH | 2004-03-30 | — | — | US | disclosed |
| US-20030216388-A1 | Cyclocarbamate derivatives as progesterone receptor modulators | WYETH | 2003-11-20 | — | — | US | disclosed |
| US-6566358-B2 | 1,4-dihydro-benzo(d)oxazin-2-one derivatives useful for treating hormone-dependent neoplastic disease is selected from uterine myometrial fibroids, endometriosis, benign prostatic hypertrophy, carcinomas, and adenocarcinoma | WYETH | 2003-05-20 | — | — | US | disclosed |
| US-20030045511-A1 | Combination regimens using progesterone receptor modulators | WYETH | 2003-03-06 | — | — | US | disclosed |
| US-6509334-B1 | This invention relates to compounds that antagonists of the progesterone receptor, their preparation and utility. Intracellular receptors (IR) form a class of structurally related gene regulators known as \"ligand dependent | AMERICAN HOME PRODUCTS CORPORATION | 2003-01-21 | — | — | US | disclosed |
| US-6444668-B1 | IN COMBINATION WITH A PROGESTIN, AN ESTROGEN, OR BOTH; ANTIPROGESTIN IS A 1,4-DIHYDRO-BENZO(D)(1.3)OXAZIN-2-ONE | WYETH | 2002-09-03 | — | — | US | disclosed |
| US-20020049204-A1 | Cyclocarbamate derivatives as progesterone receptor modulators | WYETH | 2002-04-25 | — | — | US | disclosed |
| EP-1173210-A1 | CONTRACEPTIVE COMPOSITIONS CONTAINING ANTIPROGESTINIC AND PROGESTINIC | American Home Products Corporation (US) | 2002-01-23 | — | — | EP | disclosed |
| EP-1173426-A1 | CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | American Home Products Corporation (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000066164-A1 | CONTRACEPTIVE COMPOSITIONS CONTAINING ANTIPROGESTINIC AND PROGESTINIC | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
| WO-2000066571-A1 | CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045511-A1 | Combination regimens using progesterone receptor modulators | GNRHR, PGR, PRLHR | PGR 2/4885CHEK1 1145/4885NR3C1 46/4885 |
| US-20030216388-A1 | Cyclocarbamate derivatives as progesterone receptor modulators | NR3C2, NR5A1, PGR | PGR 3/4885CHEK1 2931/4885NR3C1 4/4885 |
| US-20020049204-A1 | Cyclocarbamate derivatives as progesterone receptor modulators | NR3C1, NR5A1, CNR1 | PGR 5/4885CHEK1 2751/4885NR3C1 1/4885 |
| US-20040186101-A1 | Cyclocarbamate derivatives as progesterone receptor modulators | PGR, NR3C2, NR5A1 | PGR 1/4885CHEK1 2818/4885NR3C1 4/4885 |
| US-20090111802-A1 | CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | PGR, NR5A1, NR3C1 | PGR 1/4885CHEK1 1742/4885NR3C1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.